Pharmking schreef op 6 november 2014 15:06:
was in april...
The placement is priced at €0.49 per share, which is the average closing price of the shares over the last five trading days. A total of 30,000,000 shares, representing 8% of the outstanding share capital, will be issued to the investors. In addition the investors will receive 21,000,000 warrants with a strike price of €0.57. The exercise period of the warrants is two years.
Sijmen de Vries, Pharming CEO, said: “The strengthening of our balance sheet as result of this financing will enable us to accelerate investing in building the inherent value of the Ruconest franchise and our technology platform, including options to participate in the commercialisation of Ruconest in selected countries together with partners.”
After completion of this transaction the number of outstanding shares will increase from 374,603,750 to 403,603,750.
Dus een gemiddelde koers destijds van 0.49....Die zitten er dan dus in met verlies??